secwatch.observer — SEC 8-K summary
======================================

Issuer:     SIGA TECHNOLOGIES INC (SIGA)
CIK:        0001010086
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001140361-22-039829
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SIGA Q3 2022 revenue surges to $72.2M from $4.8M YoY; net income of $33.0M vs loss
--------------------------------------------------------------------------------

- Q3 2022 total revenues $72.2M, compared to $4.8M in Q3 2021; net income $33.0M ($0.45 diluted EPS).
- Nine-month revenues $99.4M (prior year $18.3M); net income $34.7M ($0.47 diluted EPS).
- International orders drove ~$61M in Q3 deliveries; through Oct 31, ~$77M orders from 13 customers (12 new).
- DoD awarded up to $10.7M new contract (Sep); total 2022 DoD contracts up to $18.1M for oral TPOXX.
- BARDA exercised ~$26M procurement option for IV TPOXX (Aug); monkeypox clinical trials initiated in US, UK, DRC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1010086/000114036122039829/0001140361-22-039829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1010086/000114036122039829/brhc10043715_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-039829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer